Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

inc.com/" target="_new">www.peregrineinc.com.

Bavituximab Presentation Details:

Preliminary data from a Phase II clinical trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A second presentation detailing preliminary results from a Phase I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will be discussed in a poster session from 1:00 PM to 5:00 PM EDT, also on June 1, 2009.

Title: Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.

Authors: D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, J. Shan

Time: Monday June 1, 10:30 AM

Location: Level 4, Valencia Room, W415A

Abstract No: 3005

Title: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results.

Authors: N. K. Ibrahim, L. Wong, L. Rosen, J. Shan

Time: Monday June 1, 1:00 PM to 5:00 PM

Location: Level 2, West Hall C

Abstract No: 1080

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information ab
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... its corporate partner, Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market ... a highly deliverable, next-generation drug-eluting stent (DES) specifically ...
... Data from Phase II Study Evaluating Bavituximab in ... Data from Phase I Study Evaluating Bavituximab in ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a ... the treatment of cancer and serious virus infections, ...
... Corporation (NYSE: BSX ) today announced it ... Administration (FDA) to market its TAXUS(R) Liberte (R) ... drug-eluting stent (DES) specifically designed for treating small coronary ... as small as 2.25 mm in diameter and joins ...
Cached Biology Technology:Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4
(Date:4/16/2014)... densely packed array of finger-like projections called microvilli ... line our intestines., Vanderbilt University researchers have now ... which is critical for absorbing nutrients and defending ... the journal Cell , reveal a role ... increase our understanding of intestinal pathologies associated with ...
(Date:4/16/2014)... Geologic and soil processes are to blame for significant ... to a study published recently in the Journal ... soil samples from all corners of Ohio showed that ... level of concern recommended by the U.S. Environmental Protection ... the authors, who note that regulatory levels typically are ...
(Date:4/15/2014)... CA Photosynthesis provides fixed carbon and energy for nearly ... fascinating process remain mysterious. For example, little is known ... in light intensity. More fundamentally, we do not know ... machines that perform photosynthesis in any organism. , , ... reinhardtii is a leading subject for photosynthesis research. ...
Breaking Biology News(10 mins):Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4
... of the worlds leading marine biologists will gather in Auckland ... life from the poles to the tropics. This major meeting ... Marine Life, is being jointly hosted by the National Institute ... Auckland. The Census of Marine Life is ...
... As housing developments sprout across the United States, smart ... concentrated pockets, instead of the more standard and familiar ... on the environment, affecting a smaller portion of the ... for cluster development was to protect open space, farmland, ...
... often focuses only on the numbers of vertebrate animals ... the tropics. But what about the other organisms, ... the species richness of flowering plants and mammals is ... taxonomists, ecologists, and philosophers explored the worlds southernmost forest ...
Cached Biology News:Location, location, location 2Location, location, location 3The conservation lens 2The conservation lens 3
... EnzChek Pyrophosphate Detection Kit,provides a fast, ... the inorganic pyrophosphate (PPi ) produced,by ... as DNA and,RNA polymerizations, cyclic AMP ... the enzymatic activation of fatty acids ...
... deoxynucleotidyl transferase (TdT) is an intracellular marker ... thymocytes and minor subpopulation of bone marrow ... increased numbers of TdT cells are found ... and lymphomas. Presence of TdT thus provides ...
... matrix proteins (NMPs) make up the internal structural ... such functions as DNA replication, RNA synthesis, and ... been shown to be highly insoluble in ... death releases soluble nuclear matrix proteins that can ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: